Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Kornek

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
European Journal of Neurology|February 20, 2024
Rituximab treatment in pediatric-onset multiple sclerosisMarkus Breu, Fredrik Sandesjö, Ruxandra-Iulia Milos, et al.
European Journal of Neurology|February 1, 2022
Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort studyGabriel Bsteh, Harald Hegen, Gerhard Traxler, et al.
European Journal of Neurology|January 31, 2023
Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosisGabriel Bsteh, Harald Hegen, Patrick Altmann, et al.
Neurology|September 29, 2025
Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple SclerosisGabriel Bsteh, Harald Hegen, Nik Krajnc, et al.
Multiple Sclerosis and Related Disorders|July 7, 2022
Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter studyNik Krajnc, Harald Hegen, Gerhard Traxler, et al.
JAMA Neurology|February 20, 2013
Natalizumab therapy for highly active pediatric multiple sclerosisBarbara Kornek, Fahmy Aboul-Enein, Kevin Rostasy, et al.
Nature Communications|July 14, 2025
Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1<sub>381-452</sub>-specific antibody titersHannes Vietzen, Laura M Kühner, Sarah M Berger, et al.
European Journal of Neurology|December 28, 2020
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC scoreGabriel Bsteh, Harald Hegen, Katharina Riedl, et al.
Wiener Klinische Wochenschrift|July 3, 2026
[Vaccination of immunocompromised individuals: Expert opinion - update 2026]Ursula Wiedermann, Angelika Wagner, Alexander Bartuschka, et al.
Annals of Clinical and Translational Neurology|December 17, 2024
Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical thresholdGabriel Bsteh, Harald Hegen, Nik Krajnc, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
European Journal of Neurology|February 20, 2024
Rituximab treatment in pediatric-onset multiple sclerosisMarkus Breu, Fredrik Sandesjö, Ruxandra-Iulia Milos, et al.
European Journal of Neurology|February 1, 2022
Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort studyGabriel Bsteh, Harald Hegen, Gerhard Traxler, et al.
European Journal of Neurology|January 31, 2023
Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosisGabriel Bsteh, Harald Hegen, Patrick Altmann, et al.
Neurology|September 29, 2025
Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple SclerosisGabriel Bsteh, Harald Hegen, Nik Krajnc, et al.
Multiple Sclerosis and Related Disorders|July 7, 2022
Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter studyNik Krajnc, Harald Hegen, Gerhard Traxler, et al.
JAMA Neurology|February 20, 2013
Natalizumab therapy for highly active pediatric multiple sclerosisBarbara Kornek, Fahmy Aboul-Enein, Kevin Rostasy, et al.
Nature Communications|July 14, 2025
Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1<sub>381-452</sub>-specific antibody titersHannes Vietzen, Laura M Kühner, Sarah M Berger, et al.
European Journal of Neurology|December 28, 2020
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC scoreGabriel Bsteh, Harald Hegen, Katharina Riedl, et al.
Wiener Klinische Wochenschrift|July 3, 2026
[Vaccination of immunocompromised individuals: Expert opinion - update 2026]Ursula Wiedermann, Angelika Wagner, Alexander Bartuschka, et al.
Annals of Clinical and Translational Neurology|December 17, 2024
Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical thresholdGabriel Bsteh, Harald Hegen, Nik Krajnc, et al.
Pageof 7